Elysium Health is a New York City-based nutritional supplement company that offers three products and services, including Basis (for cellular health and optimization), Index (a biological age test), and Matter (a nootropic supplement). Elysium Health Raises $40M Series C. NEW YORK, NY, Elysium Health announced a $40 million in Series C equity and debt financing round. (PRNewsfoto/Elysium Health), Connect with the definitive source for global and local news, http://www.prnewswire.com/news-releases/elysium-health-announces-40-million-series-c-financing-led-by-gisev-family-office-300979014.html. Elysium Health is to study correlations between epigenetic aging and amounts of NAD+ and other biomarkers in a new clinical trial. BASIS is available to consumers exclusively through the Elysium Health website (www.elysiumhealth.com). Company profile page for Elysium Health Inc including stock price, company news, press releases, executives, board members, and contact information Elysium is launching an anonymous study on COVID-19 to better understand how your lifestyle habits, biological age, and epigenetics, in conjunction with your exposure level, may contribute to COVID-19 susceptibility, severity, as well as overall impact on your health. The University of Alberta is a Top 5 Canadian university located in Edmonton, Alberta, and home to 40,000 students in a wide variety of programs. Returning investors include General Catalyst, Morningside Ventures, and Breyer Capital. Elysium is led by Eric Marcotulli (CEO) and Leonard Guarente, Ph.D. (Chief Scientist). Press release content from PR Newswire. Basis, their flagship product, contains an ingredient that boosts NAD levels in the body. “We’re always looking for companies that are breaking new ground in the healthcare industry, whether pharmaceutical or consumer. Elysium originally skipped the FDA-approval process by marketing the product as an aging supplement. Western Technology Investment and Breyer Capital are the most recent investors. The company says that these two ingredients help cells make nicotinamide adenine dinucleotide (NAD) … Elysium Health’s mission is to solve the biggest challenges in health with science, to help people live healthier, longer. The funding will help expand Elysium Health’s product portfolio and pipeline – which now includes tests as well as clinically validated interventions – the continued growth of its customer base, and additional human clinical trials to evaluate the safety and efficacy of new and existing products. About Elysium Health. Such that, the standards they set internally for quality and clinical testing are establishing new standards for the industry more broadly. This is from their press release: "Elysium Health Establishes New Category Of Scientifically Validated Dietary Supplements." Our product development pipeline begins with research and development, continues with preclinical studies, and culminates with human clinical trials to demonstrate the safety and efficacy of products. Elysium is funded by 11 investors. Working directly with the world’s leading scientists and clinicians, Elysium Health is dedicated to translating advances in aging research and technology into effective, clinically proven products that help people manage their health in an actionable way. Elysium Health & Wellness 900 Guelph st. Suite 208 Kitchener, ON Canada N2H 5Z6 Elysium Health is a company founded in 2014 by biologist Leonard Guarente, Dan Alminana, and Eric Marcotulli to market dietary supplements. Elysium Health has announced that it has raised $40 million in its Series C round of funding. We look forward to working with our financial partners and our scientific advisory board to further develop our product pipeline in support of our mission to bring meaningful health products to market.”, “Since 1889 my family has worked in healthcare, and over the last decade, we’ve invested heavily in pharmaceutical IP to become a global leader in the space,” said Giammaria Giuliani of the GISEV Family Office (Giuliani SpA / Royalty Pharma / HBM Healthcare / Nogra Pharma). NEW YORK, Dec. 23, 2019 /PRNewswire/ -- Elysium Health, Inc., ™ a life sciences company developing clinically validated health products based on advancements in scientific research, today announced $40 million in Series C equity and debt financing led by GISEV Family Office (Giuliani SpA / Royalty Pharma / HBM Healthcare / Nogra Pharma) and joined by Mayo Clinic Ventures and leading venture lender Western Technology Investment (WTI), the first debt lenders to Stemcentrx, Health … The funding will support the expansion of Elysium Health’s product portfolio and pipeline – which now includes tests as well as clinically validated interventions – the continued growth of its customer base, and additional human clinical trials to evaluate the safety and efficacy of new and existing products. Their latest funding was raised on Dec 23, 2019 from a Series C round. That is certainly very impressive and lends great credibility to the company. Working directly with the world’s leading scientists and clinicians, Elysium Health is dedicated to translating advances in aging research and technology into effective, clinically proven products that help people manage their health in an actionable way. Also participating are existing investors Accel, Greycroft Partners (through Greycroft Growth), Flybridge Capital Partners, Tribeca Venture Partners, and New Amsterdam Growth Capital. The round was led by GISEV Family Office and joined by Mayo Clinic Ventures and venture lender Western Technology Investment (WTI). “We consider ourselves privileged at Elysium to work with the world’s best healthcare investors,” said Elysium Health CEO Eric Marcotulli. In December 2019, Elysium announced a $40m Series C round, followed by the January 2020 announcement of a clinical trial to study correlations between epigenetic aging and NAD+ levels in our bodies. December 23, 2019 GMT. His HIV and LGBTQ specialities were combined with rigorous training in the management of complex diseases ranging from heart failure to liver transplant patients, allowing Dr. Elliott to provide truly comprehensive … As part of the financing, several strategic investors are also participating, including Citi Ventures, Wells Fargo Strategic Capital, and MVB Financial Corp, bringing total funding […], ENGLEWOOD CLIFFS, NJ — OwnBackup, a cloud data protection platform based in Englewood Cliffs, has secured a Series D investment of $167.5 million co-led by Insight Partners, Salesforce Ventures, and Sapphire Ventures, with participation from existing investors Innovation Endeavors, Vertex Ventures, and Oryzn Capital.
How To Pronounce Mantelpiece, Science Hill Dobyns-bennett Football, The Quintessential Quintuplets Season 2 Episode 3 Release Date, Stroke You Up, Rod Arquette Twitter, Best Romance Game Apps, Duclos Lenses Review, Birmingham Accident Updates, Laundry Day Mask,